NASDAQ: LQDA

Liquidia Corporation

Healthcare | Biotechnology

No licensed closing price on file for LQDA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$1.40

Liquidia Corporation (NASDAQ: LQDA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:47 UTC.

What Liquidia Corporation does

Liquidia Technologies is a biopharmaceutical company focused on treating respiratory and vascular diseases, particularly pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company generates revenue from sales of YUTREPIA, an inhaled dry powder formulation of treprostinil designed using proprietary particle engineering technology, as well as from a profit-sharing agreement with Sandoz for a generic treprostinil injection.

Summarized from Liquidia Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-17
EPS (TTM)	$1.40
Return on equity	-154.03%

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-13

2026-10-13Chief Business OfficerPerformance Stock UnitsOption exercise-3,868—
2026-10-13Chief Executive OfficerOption exercise13,833—
2026-10-13Chief Commercial OfficerOption exercise4,358—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

BlackRock, Inc.10,788,586$860.17M+96.5%
FARALLON CAPITAL MANAGEMENT, L.L.C.8,365,038$666.94M-3.4%
Caligan Partners LP8,118,892$647.32M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2024-01-19Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2022-02-04Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2022-01-04Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Why Liquidia (LQDA) Is Up 24.1% After Striking Costly Peace Deal On YUTREPIA Litigation
Yahoo2026-10-16
Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure
Yahoo2026-10-16POS
HC Wainwright & Co. Maintains Buy on Liquidia, Raises Price Target to $65
Benzinga2026-10-15POS
How Much Downside Is Left In Liquidia Stock?
Yahoo2026-10-15
Liquidia adds over 30% on United Thera. settlement; BTIG upgrades
Seeking Alpha Markets2026-10-14POS

Questions this page answers

What does Liquidia Corporation do?

When did LQDA last file with the SEC?

Liquidia Corporation's most recent SEC filing on record is a 8-K filed 2026-06-17. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:47 UTC. This page is also available as JSON at /api/data?ticker=LQDA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for LQDA and 5,000+ tickers.

Create a free account — keep LQDA

For your agent

GET /api/data?ticker=LQDA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt